Department of Oncology, Division of Palliative Medicine, University of Alberta, Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, T6G 1Z2, Canada.
Research and Evaluation Lead, Nutrition Services, Provincial Strategy, Standards and Practice, Alberta Health Services, Alberta, Canada.
Clin Nutr. 2024 Apr;43(4):989-1000. doi: 10.1016/j.clnu.2024.02.020. Epub 2024 Feb 22.
BACKGROUND & AIMS: Existing skeletal muscle index (SMI) thresholds for sarcopenia are inconsistent, and do not reflect severity of depletion. In this study we aimed to define criterion values for moderate and severe skeletal muscle depletion based on the risk of mortality in a population of patients with head and neck cancer (HNC). Additionally, we aimed to identify clinical and demographic predictors of skeletal muscle depletion, evaluate the survival impact of skeletal muscle depletion in patients with minimal nutritional risk or good performance status, and finally, benchmarking SMI values of patients with HNC against healthy young adults.
Population cohort of 1231 consecutive patients and external validation cohorts with HNC had lumbar SMI measured by cross-sectional imaging. Optimal stratification determined sex-specific thresholds for 2-levels of SMI depletion (Class I and II) based on overall survival (OS). Adjusted multivariable regression analyses (tumor site, stage, performance status, age, sex, dietary intake, weight loss) determined relationships between 2-levels of SMI depletion and OS.
Mean SMI (cm/m) was 51.7 ± 9.9 (males) and 39.8 ± 7.1 (females). The overall and sex-specific population demonstrated an increased risk of mortality associated with decreasing SMI. Sex-specific SMI (cm/m) depletion thresholds for 2-levels of muscle depletion determined by optimal stratification for males and females, respectively (male: 45.2-37.5, and <37.5; female: 40.9-34.2, and <34.2). In the overall population, Normal SMI, Class I and II SMI depletion occurred in 65.0%, 24.0%, and 11.0%, respectively. Median OS was: Normal SMI (114 months, 95% CI, 97.1-130.8); Class I SMI Depletion (42 months, 95% CI, 28.5-55.4), and Class II SMI Depletion (15 months, 95% CI, 9.8-20.1). Adjusted multivariable analysis compared with Normal SMI (reference), Class I SMI Depletion (HR, 1.49; 95% CI, 1.18-1.88; P < .001), Class II SMI Depletion (HR, 1.91; 95% CI, 1.42-2.58; P < .001).
Moderate and severe SMI depletion demonstrate discrimination in OS in patients with HNC. Moderate and severe SMI depletion is prevalent in patients with minimal nutrition risk and good performance status. Benchmarking SMI values against healthy young adults exemplifies the magnitude of SMI depletion in patients with HNC and may be a useful method in standardizing SMI assessment.
现有的骨骼肌指数(SMI)用于肌少症的标准不一致,且不能反映肌肉消耗的严重程度。本研究旨在根据头颈部癌症(HNC)患者的死亡率,为中度和重度骨骼肌消耗定义临界值。此外,我们旨在确定骨骼肌消耗的临床和人口统计学预测因素,评估在有轻微营养风险或良好表现状态的患者中骨骼肌消耗对生存的影响,最后,将 HNC 患者的 SMI 值与健康的年轻成年人进行基准比较。
1231 例连续 HNC 患者的人群队列和外部验证队列通过横断面成像测量腰椎 SMI。根据总生存(OS)进行最优分层,确定了基于性别的 2 级 SMI 消耗(I 类和 II 类)的最佳分层。调整后的多变量回归分析(肿瘤部位、分期、表现状态、年龄、性别、饮食摄入、体重减轻)确定了 2 级 SMI 消耗与 OS 之间的关系。
平均 SMI(cm/m)为男性 51.7±9.9,女性 39.8±7.1。整体和按性别划分的人群均显示出与 SMI 降低相关的死亡风险增加。通过最优分层确定的 2 级肌肉消耗的男性和女性 SMI(cm/m)消耗临界值分别为(男性:45.2-37.5,<37.5;女性:40.9-34.2,<34.2)。在整个人群中,正常 SMI、I 类和 II 类 SMI 消耗的发生率分别为 65.0%、24.0%和 11.0%。中位 OS 为:正常 SMI(114 个月,95%CI,97.1-130.8);I 类 SMI 消耗(42 个月,95%CI,28.5-55.4)和 II 类 SMI 消耗(15 个月,95%CI,9.8-20.1)。与正常 SMI(参考)相比,调整后的多变量分析显示,I 类 SMI 消耗(HR,1.49;95%CI,1.18-1.88;P<0.001)和 II 类 SMI 消耗(HR,1.91;95%CI,1.42-2.58;P<0.001)。
HNC 患者的中度和重度 SMI 消耗显示出在 OS 方面的差异。在有轻微营养风险和良好表现状态的患者中,中度和重度 SMI 消耗很常见。与健康的年轻成年人进行 SMI 值基准比较,说明了 HNC 患者 SMI 消耗的严重程度,这可能是标准化 SMI 评估的一种有用方法。